Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Case Rep Nephrol
Hlavní autoři: García Monteavaro, Camino, Peralta Roselló, Carmen, Quiroga, Borja, Baltar Martín, José María, Castillo Eraso, Lorena, de Álvaro Moreno, Fernando, Martínez Vea, Alberto, Visus-Fernández de Manzanos, María Teresa
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi Publishing Corporation 2016
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5153492/
https://ncbi.nlm.nih.gov/pubmed/28025630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/7471082
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky